CFO Clancy leaves Biogen for Alexion

Rare disease company Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) named Paul Clancy CFO, effective July 31. Clancy will step down at the end of 2Q17 from Biogen Inc. (NASDAQ:BIIB), where he is EVP of finance and CFO.

Clancy will succeed Dave Anderson, who will remain with Alexion through the transition and leave at the end of August. The company announced Anderson's departure in May along with other management changes (see BioCentury Extra, May 23). ...